Info

🌱 來自：chronic myelogenous leukemia (CML)

prognosis of chronic myelogenous leukemia (CML)

(NEJM 2017;376:917)

Chronic phase CML Rx’d w/ imatinib:

• 89% 5-y overall survival,

• 95% survival free of CML-related deaths,

• 7% progression to blast phase at 5 y

  • (NEJM 2006;355:2408).

• Pts in CCyR (~equal to QT-PCR if 1% IS)

  • have normal life expectancy.

• QT-PCR >4-log

  • ↓ can consider TKI discontinuation trial
  • (Lancet Onc 2018;19:747).

• Stage of disease at dx is strongest predictor of outcome (chronic vs. accel/blast phase)

• OS nearing nl life expectancy (if diagnosed in chronic phase) in TKI era

• Various scoring systems devised to predict outcomes at dx:

  • Sokal score
  • Hasford score (categories: low vs. intermediate vs. high; same elements as Sokal, as well as peripheral blood basophils/eosinophils) (JNCI 1998;90:850)

• ELTS (EUTOS long term survival score):
  • Categories: Low vs. intermediate vs. high; same elements as Sokal; different weighting, imatinib-based (Leukemia 2020;34(8):2138)